Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Moderna reicht Zulassungsantrag für seinen neu angepassten COVID-19-Impfstoff bei der Europäischen Arzneimittelagentur ein: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg
Moderna reicht Zulassungsantrag für seinen neu angepassten COVID-19-Impfstoff bei der Europäischen Arzneimittelagentur ein

Die Einreichung folgt auf die Empfehlung der Regulierungsbehörden und öffentlichen Gesundheitseinrichtungen auf internationaler Ebene hinsichtlich der Entwicklung von monovalenten

Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg
Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

The filing follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines

 

Pending approval, Moderna's updated COVID-19 vaccine

Tesla: Can Downgrades Make Sense After A 170% Rally?: https://www.marketbeat.com/logos/articles/med_20230630104736_tesla-can-downgrades-make-sense-after-a-170-rally.jpg
Tesla: Can Downgrades Make Sense After A 170% Rally?

Sometimes the stock market can really make you scratch your head. As investors, we’re used to being always told to follow a trend, buy into a good thing, don’t catch the falling knife. This is why

Buffett's Berkshire Increases Stake In Occidental Petroleum (OXY): https://www.marketbeat.com/logos/articles/med_20230630093651_buffetts-berkshire-increases-stake-in-occidental-p.jpg
Buffett's Berkshire Increases Stake In Occidental Petroleum (OXY)

Warren Buffett's Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) disclosed in a filing late Wednesday that it purchased an additional 2,138,250 shares of Occidental Petroleum (NYSE: OXY). Buffett's

Rally Gains Momentum On Soft PCE Data: https://www.marketbeat.com/logos/articles/med_20230630085513_chart-spx-6302023.png
Rally Gains Momentum On Soft PCE Data

The S&P 500 (NYSE: SPY) extended its summer rally after softer-than-expected PCE price data. The data is the latest in a string of good news that will help lift the market into mid-summer. The

Bank of America, JPMorgan, Goldman Sachs Set For Dividend Growth?: https://www.marketbeat.com/logos/articles/med_20230630085238_bank-of-america-jpmorgan-goldman-sachs-set-for-div.jpg
SMART Global Holdings Momentum, Room To Move Higher?: https://www.marketbeat.com/logos/articles/med_20230630084902_smart-global-holdings-momentum-room-to-move-higher.jpg
SMART Global Holdings Momentum, Room To Move Higher?

SMART Global Holdings (NASDAQ: SGH) is part of the semiconductor family, a sector that has taken on the spotlight during the past few weeks; the attention to the space was drawn after NVIDIA

Freeport-McMoRan: Analysts Bullish Ahead Of Growth Copper's Spurt: https://www.marketbeat.com/logos/articles/med_20230630083217_freeport-mcmoran-analysts-bullish-ahead-of-growth.jpg
Freeport-McMoRan: Analysts Bullish Ahead Of Growth Copper's Spurt

When you think of the metal most crucial to the rapidly growing movement toward decarbonization, lithium might pop into your mind, as its use in batteries has been widely touted. 

But copper is

The Nike Rebound Is Over; Buying Opportunity Ahead: https://www.marketbeat.com/logos/articles/med_20230630075927_chart-nke-6302023.png
The Nike Rebound Is Over; Buying Opportunity Ahead

Nike (NYSE: NKE) proved again that it can Just Do It when operating in an ever-changing business environment. The Q3 results and guidance prove the company’s resiliency but also give evidence of

Verve Therapeutics Gains 20.74% In June as Ark Funds Invest: https://www.marketbeat.com/logos/articles/med_20230629144751_verve-therapeutics-gains-20.jpg
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest

Small-cap biotech Verve Therapeutics Inc. (NASDAQ: VERV) is up 20.74% in June, with some of that gain due to Cathie Wood’s Ark funds adding shares. 

Verve, which was founded in 2018 and went

Moderna: Declining Performance And Relative Weakness: https://www.marketbeat.com/logos/articles/med_20230629122911_screenshot-2023-06-29-121344.jpg
Moderna: Declining Performance And Relative Weakness

Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion

Is it Time To Ring The Register On Paychex?: https://www.marketbeat.com/logos/articles/med_20230629110600_chart-payx-6292023.png
Is it Time To Ring The Register On Paychex?

Paychex (NASDAQ: PAYX) shares are up more than 140% from the 2020 lows, but it may be time to ring the register. The Q4 results and outlook are good enough but failed to spark a rally in the

Micron Technology: A Reversal Is Imminent: https://www.marketbeat.com/logos/articles/med_20230629090827_copy-1-of-chart-mu-6292023.png
Micron Technology: A Reversal Is Imminent

Micron Technologies (NASDAQ: MU) has been suffering through an inventory correction that has yet to run its course, but a reversal in share prices is imminent. The Q3 results, as bad as they were

McCormick Rebound Imminent: Executive Transition Complete: https://www.marketbeat.com/logos/articles/med_20230629080145_chart-mkc-6292023.png
McCormick Rebound Imminent: Executive Transition Complete

McCormick's (NYSE: MKC) price action wobbled following a better-than-expected Q2 and increased guidance. The news proves that the decision to transition Brenden Foley into the CEO position was

Google Was Just Downgraded, But This Could Be A Good Thing: https://www.marketbeat.com/logos/articles/med_20230629070102_google-was-just-downgraded-but-this-could-be-a-goo.jpg
Google Was Just Downgraded, But This Could Be A Good Thing

After watching their shares rally by more than 50% from last November, it must have been a kick in the teeth for Alphabet Inc (NASDAQ: GOOGL), better known as Google, to receive two downgrades

Rising AI & Falling Shares: Nvidia Facing New Export Restrictions: https://www.marketbeat.com/logos/articles/med_20230629065252_rising-ai-falling-shares-nvidia-facing-new-export.jpg
Rising AI & Falling Shares: Nvidia Facing New Export Restrictions

Nvidia Corp.’s (NASDAQ: NVDA) meteoric year-to-date increase of 186.60% is largely due to the company’s semiconductors that are behind the boom in artificial intelligence applications. 

But

Apple's Bull Run And Why It's Different: https://www.marketbeat.com/logos/articles/med_20230629064935_apples-bull-run-and-why-its-different.jpg
Apple's Bull Run And Why It's Different

A funny thing has been happening on Wall Street recently. Some of the biggest and brightest tech stocks have received cautious downgrades from analysts despite posting significant returns this

Das BioMed X Institute startet sein erstes Forschungsprojekt mit Sanofi zur Anwendung von künstlicher Intelligenz in der Arzneimittelentwicklung: https://www.irw-press.at/prcom/images/messages/2023/71158/BioMedX_062923_DEPRcom.001.jpeg
Das BioMed X Institute startet sein erstes Forschungsprojekt mit Sanofi zur Anwendung von künstlicher Intelligenz in der Arzneimittelentwicklung

Ein neues BioMed X-Forschungsteam wird mit Unterstützung von Sanofi eine Computerplattform entwickeln, die die Entwicklung von Medikamenten beschleunigen soll.

 

HEIDELBERG, DEUTSCHLAND /

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development: https://www.irw-press.at/prcom/images/messages/2023/71158/BioMedX_062923_ENPRcom.001.jpeg
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development

Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development.

 

HEIDELBERG, GERMANY / ACCESSWIRE / June 29, 2023 / BioMed X, a

AMD's Recent Correction: A Buying Opportunity For Investors?: https://www.marketbeat.com/logos/articles/med_20230628100045_screenshot-2023-06-28-102239.jpg
AMD's Recent Correction: A Buying Opportunity For Investors?

Advanced Micro Devices (NASDAQ: AMD) has been one of the standout performing semiconductor and NASDAQ companies of 2023. YTD shares of the semiconductor company are up about 70%, last trading near

AeroVironment's New Momentum Makes it a Value Play: https://www.marketbeat.com/logos/articles/med_20230628101337_aerovironments-new-momentum-makes-it-a-value-play.jpg
AeroVironment's New Momentum Makes it a Value Play

Shares of AeroVironment Inc. (NASDAQ: AVAV) rose by as much as 5.9% in the after-market hours of Tuesday evening. The price action stems from the company releasing its fourth quarter 2023 earnings

Unifirst: Undervalued At Rock-Bottom Prices: https://www.marketbeat.com/logos/articles/med_20230628093850_chart-unf-6282023.png
Unifirst: Undervalued At Rock-Bottom Prices

Unifirst (NYSE: UNF) is not an evident value trading at 24X its earnings outlook. The broad market S&P 500 trades at only 17X or 18X of its earnings, which is well below UniFirst and comes with a

Down Over 80%, is Pet Insurer Trupanion Worth the Risk Premium?: https://www.marketbeat.com/logos/articles/med_20230628085658_down-over-80-is-pet-insurer-trupanion-worth-the-ri.jpg
Down Over 80%, is Pet Insurer Trupanion Worth the Risk Premium?

As shareholders of pet insurer Trupanion Inc. (NASDAQ: TRUP) learned last month, when you post a net loss that's twice what Wall Street expected, things get a little fuzzy.

The May 5

Splunk Climbs 6% Since Earnings Report, May See New Buy Zone Soon: https://www.marketbeat.com/logos/articles/med_20230628083046_splunk-climbs-6-since-earnings-report-may-see-new.jpg
Splunk Climbs 6% Since Earnings Report, May See New Buy Zone Soon

Data analytics software developer Splunk Inc. (NASDAQ: SPLK) is up more than 6% since its most recent quarterly earnings report in May.  

Like many stocks, Splunk's recent price action has been

MoonLake Immunotherapeutics Makes a Moonshot on Trials: https://www.marketbeat.com/logos/articles/med_20230627135359_chart-mltx.jpg
MoonLake Immunotherapeutics Makes a Moonshot on Trials

Clinical stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive phase two clinical trial results. The company specializes in nanobodies, fragments of antibodies